DURYSTA® (bimatoprost intracameral implant) | Patient Website

Time 2022-08-26 18:43:03

Web Name: DURYSTA® (bimatoprost intracameral implant) | Patient Website

WebSite: http://www.durysta.com

ID:293204

Keywords:

bimatoprost,DURYSTA,intracameral,Website

Description:

For U.S. Residents Only Prescribing Information Important Safety Information Visit HCP Website Eye Pressure
and Glaucoma About
DURYSTA® Patient
Testimonials Resources
and FAQs Talk to Your
Eye Doctor Find-A-Doctor

SEE HER STORY NOW FIND A DOCTOR NOW GET YOUR QUESTIONS ANSWERED LEARN HOW DURYSTA® CAN HELP

Understanding the role of eye pressure in glaucoma

Consistent eye pressure control is important

The pressure inside your eye is called intraocular pressure, or IOP. When IOP is elevated, it's a major risk factor for vision loss associated with glaucoma over time. The higher the level of IOP, the greater the chance of optic nerve damage and vision loss.

1 2 3 Fluid builds up
inside your eye and
pressure increases As pressure increases,
it can damage your optic
nerve (which connects
your eye to your brain) Over time, this
damage to the optic nerve can
lead to vision loss 1 2 3 Fluid builds up inside your eye and pressure increases As pressure increases, it can damage your optic nerve (which connects your eye to your brain) Over time, this damage to the optic nerve can lead to vision loss 1 2 3 Fluid builds up inside your eye and pressure increases As pressure increases, it can damage your optic nerve (which connects your eye to your brain) Over time, this damage to the optic nerve can lead to vision loss

GLAUCOMA VISION
LOSS SIMULATOR

This simulator shows you how elevated eye
pressure may affect your vision over time

Just 1 DURYSTA® implant works for several months

DURYSTA® is a tiny, dissolvable implant your eye doctor places in your eye

The first and only FDA-approved dissolvable ocular implant to reduce eye pressure in people with open angle glaucoma or high eye pressure (ocular hypertension)Just 1 DURYSTA® implant reduced eye pressure for 15 weeks in clinical studiesAs DURYSTA® dissolves, it automatically releases medicine to help reduce high pressure inside your eye

DURYSTA® should not be given in the same eye more than once.

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

Not an actual patient.

Meet Monica, a real glaucoma patient

Watch the video and learn about her
treatment journey with DURYSTA®

Monica started with eye drops to lower her eye pressure.
Later, her doctor recommended DURYSTA®
for several months of eye pressure control.

Learn why DURYSTA® has met her expectations.

Monica is a real DURYSTA® patient.

Resources to help on your own DURYSTA® journey

Find out if DURYSTA® is right for
you with this checklist.

Download it now and get
the conversation started.

Find out how the Savings
Program could benefit you.

Download the Savings Program
Flashcard to learn more.

Frequently Asked Questions About DURYSTA®

What is DURYSTA®?

DURYSTA® is a prescription medicine and drug delivery system for the eye for lowering eye pressure in patients with open angle glaucoma or high eye pressure (ocular hypertension). DURYSTA® should not be given in the same eye more than once.

How is the procedure done?

DURYSTA® is placed directly inside your eye, 1 time only per eye, by your eye doctor.

DURYSTA® should not be given in the same eye more than once.

How does DURYSTA® work?

As DURYSTA® dissolves, it automatically releases medicine to help reduce high pressure inside your eye. Once in place, it does the dosing for you.

How might DURYSTA® help me?

In 2 clinical studies for DURYSTA®, eye pressure was reduced for 15 weeks.

Does DURYSTA® have any side effects?

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

See full Prescribing Information for complete safety information.

How long will DURYSTA® work?

One DURYSTA® implant lasts for several months.

Is there a savings program?

Yes! Ask your doctor if you're eligible to pay as little as $0^{*
for up to one implant per eye}

^{*Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for DURYSTA®. Offer not valid for patients receiving prescription drug reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See Program Terms, Conditions, and Eligibility Criteria here.}

Does DURYSTA® contain preservatives?

No, DURYSTA® is a preservative-free option for lowering high eye pressure.

How small is the implant?

DURYSTA® is tiny.

It's smaller than the
“I” in LIBERTY on a dime! It's smaller than
the “I” in LIBERTY
on a dime!Dime enlarged to show detail.

DURYSTA® may be right for you, too

Ask your eye doctor about DURYSTA®

Find out if DURYSTA® is right for you.

Here are some things to think about before speaking to your eye doctor:

Is elevated eye pressure an issue?

Do you understand elevated eye pressure and the risks associated with it?

Do you have difficulty applying your eye drops every day? (Hard time using them, or forgetting?)

Find an eye doctor near you who can prescribe DURYSTA®

CLICK HERE

Ask your doctor if you're eligible to pay
as little as $0^{* for up to one implant per eye}

^{*Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for DURYSTA®. Offer not valid for patients receiving prescription drug reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program.Program Terms, Conditions, and Eligibility Criteria:1. This offer is valid only for patients 18 years of age or older who have commercial insurance coverage and a valid prescription for DURYSTA® (bimatoprost intracameral implant) 10 mcg for an approved use. 2. This offer is not valid for use by patients receiving prescription reimbursement under any federal, state, or government-funded healthcare programs (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs); private indemnity or HMO insurance plans that reimburse patients for the entire cost of their prescription drugs; or where prohibited by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, patient will no longer be eligible for this offer and must call IQVIA Inc. at 1-833-DURYSTA®, option 2 to stop program participation. This offer is not valid for cash-paying patients. 3. Depending on insurance coverage, eligible patients whose commercial insurance plan covers DURYSTA® may pay as little as $0 for each of up to one (1) DURYSTA® implant per eye and eligible patients whose commercial insurance plan does not cover DURYSTA® may pay as little as $250 for each of up to one (1) DURYSTA® implant per eye. This offer applies to the implant only and does not apply to costs for any other medication, procedure, or diagnostic service. Check with healthcare provider and insurance plan for discount. Maximum reimbursement limit of $1700.00 per eye applies; patient out-of-pocket expense will vary. 4. Patients may not seek reimbursement for value received from the DURYSTA® Savings Program from any third-party payers. 5. Offer applies to implants administered before the program expires on June 30, 2022. 6. Allergan, an AbbVie company, reserves the right to rescind, revoke, or amend this offer without notice. 7. Offer good only in the USA, including Puerto Rico. Patients residing in or receiving treatment in certain states may not be eligible to participate in this program. 8. Void if prohibited by law, taxed, or restricted. 9. This offer is not transferable. The selling, purchasing, trading, or counterfeiting of this offer is prohibited by law. 10. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. 11. This offer is not health insurance. 12. Program expires June 30, 2022. 13. By redeeming this offer, patient represents they meet the eligibility criteria above and patient understands and agrees to comply with the terms and conditions of this offer.For questions about the program, please call 1-833-DURYSTA®, option 2.Program managed by IQVIA Inc. on behalf of Allergan, an AbbVie company.}

INDICATIONS AND USAGE AND IMPORTANT SAFETY INFORMATION

APPROVED USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA® should not be used if:

You have any infection or suspected infection in your eye or surrounding eye area You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant) The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn You are allergic to any of its ingredients

DURYSTA® may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA® more than once in each eye. DURYSTA® should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA® should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA® may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA® should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA® may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA® may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye redness, sensitivity to light, eye pain, or a change in vision, after an injection. Your doctor should monitor you following DURYSTA® administration.

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE COLLAPSE EXPAND

DURYSTA® should not be used if:

You have any infection or suspected infection in your eye or surrounding eye area You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant) The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn You are allergic to any of its ingredients

DURYSTA® may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA® more than once in each eye. DURYSTA® should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA® should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA® may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA® should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA® may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA® may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye redness, sensitivity to light, eye pain, or a change in vision, after an injection. Your doctor should monitor you following DURYSTA® administration.

The most common side effect involving the eyes reported in patients using DURYSTA® was eye redness. Other common side effects reported were: feeling like something is in your eye, eye pain, being sensitive to light, a blood spot on the white of your eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

APPROVED USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

Please see full Prescribing Information.

© 2022 AbbVie. All rights reserved. DURYSTA® and its design are registered trademarks of Allergan, Inc., an AbbVie company.

All other trademarks and product names are the property of their respective owners.

US-DUR-21061802/22

TERMS OF USE PRIVACY STATEMENT CONTACT US ABOUT AbbVie SITE MAP COOKIES SETTINGS

Brought to you by

You are now leaving Durysta.com

The information provided in this website is intended for U.S. healthcare professionals only. I certify that I am a U.S. healthcare professional.

YES NO

You are now leaving Durysta.com

PROCEED

×

AbbVie Inc. and Allergan plc are a new combined company. We will continue to honor any Allergan-provided privacy notices for personal information previously collected, used, and maintained by Allergan. Going forward, personal information will be processed by this website according to AbbVie’s privacy notice https://www.abbvie.com/privacy.html.

TAGS:bimatoprost DURYSTA intracameral Website

<<< Thank you for your visit >>>

Hot Websites